Pfizer Phase 3 AXIS 1032 trial meets primary endpoint
Pfizer said that Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3. Pfizer Oncology Business Unit Clinical Development senior
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.
Of the additional sites, the Stanford Cancer Center (Stanford, California) under principal investigator Jason Gotlib, has already commenced enrolling patients, additionally the company will start recruiting patients in
Synthon has also completed registration procedures for Tamsulosin, reported PharmaLive.com. Tamsulosin, an a1a-selective alpha blocker, contains the active ingredient Tamsulosin hydrochloride. Developed by Yamanouchi Pharmaceuticals (now part of